Industries > Pharma > Global Neurovascular Devices Market Forecast to 2027

Global Neurovascular Devices Market Forecast to 2027

Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices

PUBLISHED: 11 January 2018
PAGES: 152
PRODUCT CODE: PHA0274

Clear
WOOCS 2.2.1

The global neurovascular devices market is expected to grow at a CAGR of 10.3% in the first half of the forecast period. In 2016, the Cerebral Embolization and Aneurysm Coiling Devices segment held the largest share in the global neurovascular devices market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 152-page report you will receive 85 charts– all unavailable elsewhere.

The 152-page report provides clear detailed insight into the global neurovascular devices market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Global Neurovascular Devices Market Forecast to 2027

Report Scope

• Global Neurovascular Devices market forecasts to 2027

• This report also breaks down the revenue forecast for the global neurovascular market by submarket
– Cerebral Embolization and Aneurysm Coiling Devices
– Cerebral Angioplasty and Stenting Systems
– Support Devices
– Neurothrombectomy Devices

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– The US
– EU5: Germany, France, the UK, Italy, Spain
– Japan
– BRIC: Brazil, Russia, India, China
– Rest of the World (RoW)

• Our study gives qualitative analysis of the neurovascular devices market. It discusses the SWOT analysis of the neurovascular devices market.

• Our study discusses the selected leading companies that are the major players in the neurovascular devices industry:
– Stryker Corporation
– Medtronic
– Johnson & Johnson
– Terumo
– Penumbra

Visiongain’s study is intended for anyone requiring commercial analyses for the global b neurovascular devices market. You find data, trends and predictions.

Buy our report today Global Neurovascular Devices Market Forecast to 2027: Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Neurovascular Devices Market Forecast to 2027


Download sample pages

Complete the form below to download your free sample pages for Global Neurovascular Devices Market Forecast to 2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category